ARA-290 (Cibinetide): A Non-Blood-Building EPO Fragment With Early, Conflicted Human Data

ARA-290, also called cibinetide, is an experimental peptide built from a small piece of erythropoietin (EPO) — the hormone best known for telling your body to make red blood cells. The thinking behind ARA-290 is simple: keep EPO’s tissue-repair and anti-inflammatory effects, but leave out the blood-building part. So far it has been tested in only a handful of small human trials for nerve damage, and the early results are real but limited. There is no approved product anywhere in the world, and nearly all of the encouraging human data comes from the same group of researchers connected to the company developing it.

What it is

ARA-290 is a short, lab-made peptide — just 11 amino acids (the building blocks that make up proteins). It copies the outward-facing surface of one region (called helix B) of erythropoietin. Its full sequence is pyroGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser. Because it mimics only a small surface patch instead of the whole hormone, it is missing the part of EPO that would tell the body to make red blood cells.

The proposed way it works rests on the idea that EPO actually has two separate jobs, each handled by a different receptor (a docking spot on a cell that the hormone plugs into). One receptor — the classic EPO receptor, which works as a matched pair — drives red-cell production. The other, which the developers call an “innate repair receptor” (a combination of the EPO receptor joined to the β-common receptor, also known as CD131), is said to handle tissue protection, calming inflammation, and helping cells survive. ARA-290 was designed to switch on this repair receptor while leaving the blood-building one alone.

It’s worth being honest here: the “innate repair receptor” idea comes mostly from one research group (Brines, Cerami, and their collaborators), and the exact make-up of that receptor combination has been debated in the wider EPO research rather than settled. A 2016 study suggested ARA-290 may ease pain partly by acting on the TRPV1 channel (a sensor on nerves involved in pain and heat). These are findings from cells and animals — a reasonable hypothesis with supporting lab data, but not established fact and not proof that it helps people.

The claims

In proper clinical research, ARA-290 has been studied for a narrow set of conditions: small-fiber neuropathy (damage to the tiny nerves that sense pain and temperature) and the nerve pain that comes with sarcoidosis (an inflammatory disease that can affect many organs) — this is the lead program — plus painful diabetic neuropathy with some metabolic measurements in type 2 diabetes, and diabetic macular edema (fluid build-up in the central part of the retina, in a small eye study). In animals and cell models it has been explored across a much wider range of tissue-injury situations — stroke, kidney injury, heart protection, wound healing, and more — but all of that is still preclinical (tested only in the lab or in animals, not yet in people).

Separately, peptide sellers and “longevity” or biohacking websites promote ARA-290 for general “nerve repair,” “anti-inflammation,” “tissue healing,” and recovery. These marketing claims reach far beyond what the trials actually tested — which was specific neuropathy patients over short periods (mostly 28 days). Many of these pages also post dosing instructions; those are not backed by any regulatory approval and fall outside legitimate medical use.

The evidence

There is genuine human trial data, but it is small, short, early, and heavily conflicted (meaning the people who studied it also had a stake in its success).

The most important study is a Phase 2b randomized controlled trial (a study where people are randomly assigned to the drug or a dummy treatment) in sarcoidosis-related small-fiber neuropathy, published in 2017 and registered as NCT02039687. It enrolled 64 patients split between placebo (an inactive dummy) and three doses (1, 4, and 8 mg given by subcutaneous injection — under the skin — daily for 28 days). It hit its main pre-planned goal at the 4 mg dose: compared with placebo, the area of corneal nerve fibers (nerves in the surface of the eye, used as a stand-in measure of nerve health) improved by 697 µm² (P=0.012, meaning the result was unlikely to be down to chance). The 1 mg and 8 mg doses did not reach that bar — an unusual pattern where the middle dose did better than the highest one. A measure of regrowing skin nerve fibers (GAP-43+) also rose at 4 mg (P=0.035). Notably, the overall change in pain was not statistically significant (it could have been chance).

An earlier sarcoidosis pilot trial (2013) reported less nerve pain and more corneal nerve fiber density. A Phase 2 trial in type 2 diabetes (2014), using 4 mg daily for 28 days, reported improvements in HbA1c (a measure of average blood sugar over recent months), blood fats, and a pain questionnaire, with the authors saying they found no safety concerns.

But the picture isn’t all positive. A very small Phase 2 trial in diabetic macular edema (2020, only about 8–9 patients, 12 weeks) failed on its main objective measures — there was no improvement in vision sharpness, retinal thickness, retinal sensitivity, or tear production — and only a patient-reported quality-of-life questionnaire improved.

What’s missing matters just as much as what exists:

• No Phase 3. There has been no large, properly powered, multi-center study to confirm the findings.
• No independent replication. The positive human trials share the same core researchers and developer (Araim; Brines, Cerami, and Dahan show up again and again as authors) — a serious conflict-of-interest concern.
• Surrogate endpoints. The main outcomes are nerve-fiber measurements and symptom questionnaires (stand-in markers), not solid clinical results or long-term function.
• Tiny, brief studies. The largest trial had 64 patients; in total, roughly 100 people have taken it in published studies, mostly for 28 days.
• No independent systematic review. The reviews that exist are written narratively by the same developer-linked group, not by independent reviewers.

The animal and lab work is broader and supportive — including long-lasting pain relief in rats, along with calming of the spinal microglia response (immune cells in the spinal cord that can amplify pain) — but supportive preclinical data is not the same as proof.

Safety and side effects

Across the small published trials, ARA-290 was generally well tolerated at subcutaneous (under-the-skin) doses up to 4–8 mg per day for 28 days (12 weeks in the tiny eye study). The most commonly reported effects were mild, short-lived reactions at the injection site and occasional mild headaches. No serious side effects were blamed on the drug, and the macular edema study found no anti-cibinetide antibodies (signs that the immune system was reacting against the drug).

A key part of the design is that, because ARA-290 doesn’t switch on the blood-building EPO receptor, it isn’t expected to cause the classic dangers of EPO and similar drugs — too many red cells (polycythemia), blood clots, or high blood pressure. But that’s an expectation supported by preclinical data, not something proven in large numbers of people.

The limits here are serious. The entire safety record rests on roughly 100 patients, almost all studied for 28 days or less, all in monitored trials, all tied to the developer. We don’t know what long-term or ongoing use does. Effects during pregnancy, alongside other medical conditions, or with unregulated gray-market material — where the identity, purity, dose, and possible contaminants are all unknown — are completely uncharted. The fact that no harm turned up in tiny, short trials is not proof that it’s safe over the long run.

Legal and regulatory status

ARA-290 (cibinetide) is investigational only. It is not approved by the FDA, the EMA (the European Medicines Agency), or any other regulator, for any use, anywhere in the world.

In the United States it holds Orphan Drug and Fast Track designations for neuropathic pain in sarcoidosis (orphan status reported July 2016). In the European Union it holds orphan designation EU/3/13/1191, granted 7 October 2013 for sarcoidosis, with sponsorship transferred to a Dublin-based company in 2019. These designations are incentives meant to encourage development (for example, of treatments for rare diseases) — they are not marketing approvals, and no approved product exists.

For competitive athletes, ARA-290 is not named outright on the WADA (World Anti-Doping Agency) Prohibited List, but it is an EPO-derived agent that doesn’t build red cells. WADA’s Section S2 bans EPO-receptor agonists (substances that activate the EPO receptor) and, under S2.1.5, “innate repair receptor agonists” (with asialo-EPO and carbamylated EPO listed as named examples), plus a catch-all for substances with a similar structure or biological effect. On that basis, ARA-290 is best treated as banned at all times under S2 by class, even though it isn’t listed by name.

Because there is no approval and no real prescription route, what’s sold online is “research-use-only” or “not for human consumption” material of unverified identity, purity, and dose — completely outside any regulatory oversight.

Bottom line

ARA-290 is one of the more scientifically interesting investigational peptides: a clever attempt to separate EPO’s tissue-repair effects from its blood-building ones. The human data is real — including a Phase 2b trial in sarcoidosis neuropathy that met its main nerve-fiber goal — which puts it ahead of compounds that have only been tested in animals. But that data is also small, short, built on stand-in measurements, almost entirely produced by the developer’s own group, and shadowed by at least one clearly negative trial. There is no Phase 3, no independent replication, and no approval anywhere. The honest grade is preliminary human: encouraging signals that haven’t been confirmed. Anyone who comes across ARA-290 sold for “nerve repair” or general recovery is looking at marketing that runs well ahead of the evidence.

Sources

• Helix-B surface peptide, PNAS 2008 (PMID 18676614)
• Tissue-protective EPO derivatives, Science 2004 (PMID 15247477)
• EPO/β-common heteroreceptor, PNAS 2004 (PMID 15456912)
• TRPV1 pain mechanism, Peptides 2016 (PMID 26774587)
• Sarcoidosis pilot RCT, Mol Med 2013 (PMID 24136731)
• Type 2 diabetes Phase 2, Mol Med 2014 (PMID 25387363)
• Sarcoidosis Phase 2b, IOVS 2017 (PMID 28475703)
• Trial registry NCT02039687
• Diabetic macular edema Phase 2, JCM 2020 (PMID 32674280)
• Narrative review, Expert Opin Investig Drugs 2014 (PMID 24555851)
• Long-term pain relief + microglia, Mol Pain 2014
• EMA orphan designation EU/3/13/1191
• FDA orphan status (trade press)
• WADA Prohibited List 2026